The increase in semaglutide prescriptions may be attributed to its demonstrated efficacy in promoting weight loss
A 2025 study published in Obesity found that GLP1 users lost 7.7% of body weight on semaglutide and 12.4% on tirzepatide after one year, roughly half the weight loss seen in randomized trials
Chronic stress and anxiety demonstrably impair working memory, attention, and executive function through elevated cortisol and altered prefrontal cortex activity
Sour cherry flavored, L-carnitine and Pantothenic Acid containing food supplement liquid with Sweeteners
Consistency With Known Injury Patterns Claims are stronger when injuries match patterns seen across many cases, such as: vomiting dehydration kidney injury rapid weight loss gallbladder disease GLP-1 gastric slowing gastroparesis or obstruction Consistency with known adverse-event patterns improves plausibility
Regarding the dosage of LC, Musazadeh et al